Prokidney Corp. (PROK) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Prokidney reported revenue of $893,000, up 1075.0% from $76,000 the year before. Net income was -$69.0M (a -7725.2% net margin), or -$0.52 per diluted share. Operating margin was -18477.8%. Operating activities generated -$120.1M of cash, leaving -$135.3M of free cash flow. At fiscal year end, Prokidney held $335.6M in total assets against $34.8M in total liabilities, including $108.5M of cash and equivalents.
Open the full interactive Prokidney financials → Quarterly statements, key ratios, valuation history and price charts.
Prokidney Key Stats
| Share Price | $1.57 |
|---|---|
| Market Cap | $292.9M |
| 52-Week Range | $1.33 – $3.30 |
| Shares Outstanding | 186.6 million (basic, 2026 Q2) |
Prokidney Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $76,000 | $893,000 |
| Operating Income | -$153.0M | -$151.5M | -$183.7M | -$165.0M |
| Pre-Tax Income | -$147.2M | -$129.5M | -$163.9M | -$151.2M |
| Income Tax | $896,000 | $6.0M | -$598,000 | $414,000 |
| Net Income | -$148.1M | -$35.5M | -$61.2M | -$69.0M |
| Diluted EPS | -$0.23 | -$0.57 | -$0.62 | -$0.52 |
Prokidney Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $217,000 | $225,000 | $226,000 | $150,000 |
| Net Income | -$16.5M | -$19.2M | -$20.0M | -$28.4M |
| Diluted EPS | -$0.12 | -$0.14 | -$0.14 | -$0.15 |
Prokidney Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $490.3M | $60.6M | $99.1M | $108.5M |
| Current Assets | $504.7M | $374.1M | $395.9M | $280.7M |
| Total Assets | $518.0M | $420.6M | $441.1M | $335.6M |
| Current Liabilities | $10.9M | $25.0M | $36.2M | $30.7M |
| Total Liabilities | $13.1M | $29.2M | $39.4M | $34.8M |
| Shareholders' Equity | -$1.10B | -$1.10B | -$995.0M | -$1.01B |
Prokidney Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$77.1M | -$90.1M | -$126.4M | -$120.1M |
| Cash From Investing | -$1.7M | -$330.0M | $20.4M | $104.0M |
| Cash From Financing | $548.5M | -$9.6M | $144.4M | $25.6M |
| Free Cash Flow | -$78.9M | -$124.3M | -$155.9M | -$135.3M |
Figures from Prokidney's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Prokidney financials page for every line item.
Prokidney Company Profile
| Ticker | PROK |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Winston-Salem, North Carolina |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001850270 |
Frequently Asked Questions
What was Prokidney's revenue in fiscal 2025?
Prokidney (PROK) reported revenue of $893,000 for fiscal 2025.
What is Prokidney's annual revenue history?
Prokidney's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $76,000; 2025: $893,000.
What was Prokidney's net income in fiscal 2025?
Prokidney reported net income of -$69.0M for fiscal 2025.
What was Prokidney's earnings per share (EPS) in fiscal 2025?
Prokidney's diluted EPS was -$0.52 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Prokidney generate in fiscal 2025?
Prokidney generated -$135.3M of free cash flow in fiscal 2025.
What was Prokidney's revenue last quarter?
In its most recent reported quarter (2026 Q2), Prokidney reported revenue of $150,000.
How many shares of Prokidney are outstanding?
Prokidney reported a weighted average of 186.6 million basic shares outstanding in 2026 Q2.
What is Prokidney's market cap?
Based on its latest closing price, Prokidney (PROK) has a market capitalization of about $292.9M.
When does Prokidney's fiscal year end?
Prokidney's fiscal year end, as registered with the SEC, is December 31.
Where is Prokidney headquartered?
Prokidney lists its business address in Winston-Salem, North Carolina in its SEC filings.
Prokidney Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →